TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of all ages diagnosed with HT-1.~* Patients currently well-controlled, as judged by the investigator, on twice daily (or more frequent) dosing with Orfadin.~* Stable lab values, including liver values \<2 ULN (ALP, ALT, AST, bilirubin, INR).~* Women of childbearing potential willing to use adequate contraception~* Signed informed consent/assent.~Exclusion Criteria:~* Patients who have been previously treated with once daily Orfadin, even if later converted to twice daily dosing.~* Any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion.~* Enrollment in another concurrent clinical interventional study within three months prior to inclusion in this study.~* Pregnant women.~* Lactating women.~* Previous liver transplantation.~* Patients who have recently (past 4 weeks prior to inclusion) started any new medication for a previously undiagnosed illness/disease.~* Known hepatitis B, hepatitis C or HIV infection.~* Foreseeable inability to cooperate with given instructions or study procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitisinone treatment group (Type: EXPERIMENTAL): All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TTP399 in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* People diagnosed with T1DM, confirmed diagnosis prior to 40 years of age and a diagnosed for minimum of 1 year.~* Type 1 diabetics using either continuous subcutaneous insulin infusion (with lispro or aspart) or multiple daily doses of insulin~* Willing to use adequate contraception~* No major surgeries or significant injuries within the past year and without an active infection.~Exclusion Criteria:~* Diagnosis of T2DM, severely uncontrolled T1DM, maturity-onset diabetes of the young, insulin-requiring T2DM, other unusual or rare forms of diabetes mellitus, diabetes resulting from a secondary disease~* Receipt of an investigational product within 30 days of the Screening Visit or any therapeutic protein or antibody within 90 days prior to Screening Visit or any previous treatment with TTP399.~* Living in the same household or related to another participant in this study.~* Two severe episodes of hypoglycemia that required assistance by a third party within 3 months of Screening Visit~* Use of antidiabetic medications other than insulin 3 months prior to Screening Visit, systemic corticosteroids 1 month prior to Screening Visit, weight loss medication 2 weeks prior to Screening Visit, and antipsychotic medications 3 months prior to Screening Visit.~* Participation in any formal weight loss program or contemplating such therapy during the trial.~* Recent history of use of non-prescribed controlled substances or illicit drugs.~* Current alcoholism or a history of excessive alcohol consumption within 2 years prior to screening~* History or presence of symptomatic autonomic neuropathy or chronic gastrointestinal disease.~* Personal history of long QT syndrome.~* Blood donation of approximately 1 pint (500 mL) within 8 weeks before Screening Visit~* History of hemolytic anemia or chronic transfusion requirement.~* History of cancer, other than non-melanoma skin cancer or uterine cervical cancer that required therapy in the past 5 years.~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TTP399 400 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* A male or female who completed the primary vaccination phase of the HAB-160 study (NCT 00603252).~* Written informed consent obtained from the subject.~* If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after the vaccination.~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the challenge dose, or planned use during the study period.~* History of any hepatitis A or hepatitis B vaccination or infection since the primary vaccination study.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Acute disease at the time of enrolment.~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Twinrix Group (Type: EXPERIMENTAL): Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
- Engerix + Havrix Group (Type: ACTIVE_COMPARATOR): Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
- HB VAX PRO + Vaqta Group (Type: ACTIVE_COMPARATOR): Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous Magnesium During Robot Assisted Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Robot assisted prostatectomy~Exclusion Criteria:~* Allergy to magnesium~* Chronic pain~* Chronic opioid use~* Chronic NSAID use~* Renal dysfunction~* Liver dysfunction~* Cardiac arrythmia~* Seizure

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium group (Type: EXPERIMENTAL): Intravenous administration of Magnesium Sulfate
- Control group (Type: PLACEBO_COMPARATOR): Intravenous administration of normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A subject must be 12 years of age or older, of either sex, and of any race.~* A subject must have at least a 2-year history of SAR which exacerbates during the study season.~* A subject must have a positive skin prick test response to an appropriate seasonal allergen at Visit 1.~* A subject must be clinically symptomatic at the Screening and Baseline Visits.~Exclusion Criteria:~* A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.~* A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days prior to the Screening Visit.~* A subject who has used any drug in an investigational protocol in the 30 days prior to the Screening Visit.~* A subject who is participating in any other clinical study.~* A subject who is part of the staff personnel directly involved with this study.~* A subject who is a family member (parent, spouse, or sibling) of the investigational study staff.~* A female subject who is breast-feeding, pregnant, or intends to become pregnant.~* A subject previously randomized into this study.~* A subject who has a family member (parent, spouse, or sibling) currently enrolled in this study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Mometasone furoate nasal spray 200 mcg QD (once per day)
- Arm 2 (Type: PLACEBO_COMPARATOR): Matching placebo nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Naïve HIV POC Monotherapy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic HIV-1 infection~* HIV-1 plasma viral load at screening visit above 5000 HIV-1 RNA copies/ml~* Male, aged above 18 years and less than 65 years of age~* Adequate method of birth control~* Subject has never received an antiretroviral agent (NRTI, NNRTI, PI, entry inhibitor or integrase inhibitor) for the treatment of HIV and agrees not to start antiretroviral therapy prior to enrollment or subject has only received a short course of treatment for less than 14 days and has been off treatment for at least 8 weeks~* Subject has no primary mutation in the reverse transcriptase (RT) gene associated with resistance to RT inhibitors and no major mutation in the protease gene associated with resistance to PIs determined by genotypic resistance testing at screening~Exclusion Criteria:~* History or suspicion of alcohol or drug abuse which in the Investigator's opinion may lead to non-compliance~* CD4 count \< 350 cells/mm3~* Life expectancy of less than 6 months~* Receipt of an investigational drug within 30 days prior to the trial drug administration~* Receipt of any vaccine within 30 days of screening visit~* Acute HIV-1 infection (seroconversion illness)~* Acute hepatitis A or acute or chronic hepatitis B or C infection~* Currently active acquired immune deficiency syndrome (AIDS)-defining illness (Category C conditions according to the Centers for Disease Control \[CDC\] Classification System for HIV Infection 1993)~* No clinically relevant laboratory abnormalities Renal impairment: serum creatinine \> 1.5 x ULN~* Febrile illness within 120 hours prior to dosing~* History of severe drug allergy or hypersensitivity~* Significant cardiac dysfunction

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RDEA806 400 mg (Type: EXPERIMENTAL): Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
- RDEA806 600 mg (Type: EXPERIMENTAL): Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
- RDEA806 800 mg (Type: EXPERIMENTAL): Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
- RDEA806 1000 mg (Type: EXPERIMENTAL): Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture~* Have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds \[lbs\]) and no more than 100 kg (220 lbs).~* Provision of signed and dated, written informed consent prior to any study specific procedures~Exclusion Criteria:~* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study~* History of haemophilia, von Willebrand's disease, lupus anticoagulant or other diseases/syndromes that can either alter or increase the propensity for bleeding~* A personal history of vascular abnormalities including aneurysms; a personal history of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior to the screeening visit; or history suggestive of peptic ulcer disease~* History of frequent and/or significant nose bleed or clinically significant non traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Ticagrelor 90 mg as a whole tablet
- B (Type: EXPERIMENTAL): Ticagrelor 90 mg tablet crushed and suspended in water
- C (Type: EXPERIMENTAL): Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with histologically or cytologically proven, CD 20+, diffuse large B-cell lymphoma,~* Relapse after first or second CR, PR or less than PR to first-line treatment for the rituximab-naïve patients, OR relapse after first or second CR with a minimum delay of 12 months between the last rituximab infusion and the inclusion for the rituximab-experienced patients~* Aged 18 - 75 years~* Not eligible for autologous transplantation~* Previously treated with chemotherapy containing anthracycline, with or without rituximab~* ECOG performance status 0 to 2~* With a minimum life expectancy of 3 months~* Having signed informed consent form prior to enrollment~Exclusion Criteria:~* Burkitt's, mantle cell, T-cell lymphomas~* CD 20-negative lymphoma~* HIV or HBV related disease~* Central nervous system or meningeal involvement by the lymphoma~* Not previously treated with anthracycline-containing regimens~* Contraindication to any drug contained in the R-GEMOX chemotherapy regimen~* Any serious active disease or co-morbid medical condition (according to the investigator's decision),~* Poor renal function (creatinine level \> 150micromol/l), poor hepatic function (total bilirubin level \> 30mmol/l, transaminases \> 2.5 maximum normal level) unless these abnormalities are related to the lymphoma~* Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l, unless related to bone marrow infiltration~* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study~* Any radiotherapy during the four weeks before inclusion~* Pregnant or lactating woman~* Adult patient unable to give informed consent because of intellectual impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- R-GEMOX (Type: EXPERIMENTAL): Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Present with GPP or EP based on an investigator-confirmed diagnosis and meet the associated criteria~  * GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare (MHLW) at screening and baseline regardless of IL-36 mutation status.~ * EP: Diagnosed to have BSA ≥80% involvement (with inflammatory erythema) at screening and baseline.~* Candidates for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control during the study~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* History of drug-induced psoriasis~* Concurrent or recent use of any biologic agent~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study~* Have previously received ixekizumab~* Serious disorder or illness other than psoriasis~* Serious infection within the last 12 weeks~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed of Graves' Disease~Exclusion Criteria:~* Pregnancy~* Allergy to ATD, Alanine aminotransferase (ALT) or asparate aminotransferase (AST) above 2 times of upper normal range~* Non-compliance because of psychiatric or other serious diseases, or unwillingness to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MMI+IID group (Type: EXPERIMENTAL): MMI,methimazole；IID,intrathyroid injection of dexamethasone
- MMI Group (Type: ACTIVE_COMPARATOR): MMI,methimazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of post-stroke lower limb spasticity for at least 3 months~* Minimum body weight of 50 kg~* Never treated with botulinum toxin of any serotype for any reason, or if previously treated with botulinum toxin of any serotype, if previously treated for spasticity in the affected lower limb, must have been administered~  * 20 weeks before Day 1, or if previously treated for any other indication must have been administered ≥12 weeks prior to Day 1~Exclusion Criteria:~* Spasticity in the opposite leg that requires treatment~* Casting of the study limb within 6 months or planned casting during the first 12 weeks of the study~* Treatment modalities in the study limb including ultrasound, electrical nerve stimulation, electrical stimulation, acupuncture within 1 month of Day 1 or treatments planned during the study~* Not able to perform 10 meter walking test independently with or without assistive device~* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- botulinum toxin Type A (Type: EXPERIMENTAL): Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
- Normal Saline (Placebo) Followed by botulinum toxin Type A (Type: OTHER): Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete